Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Snapshots of recent studies of bevacizumab on AMD and related conditions

Nov. 23, 2006

Treatment update on macular edema: snapshots of recent studies

Nov. 22, 2006

Lucentis recommended for approval in E.U. for wet AMD

Nov. 20, 2006

New agent for glaucoma disclosed in recent Johns Hopkins University patent

Nov. 15, 2006

SPI-0023: a novel ciclosporin formulation for ophthalmic use

Nov. 14, 2006

AzaSite Plus begins phase I safety study

Nov. 10, 2006

OcuCure uses seed funding to advance compounds for AMD

Nov. 10, 2006

CGC-11047 studied in patients with AMD

Nov. 10, 2006

Lux licenses ciclosporin-eluting silicone matrix ocular implant from NIH

Nov. 9, 2006

MacuSight's proprietary sirolimus formulation begins phase I study in wet AMD

Nov. 6, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...